BS_QEYPFYHD
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 89.76
- os_event
- false
- age_years
- 13.773
- sex
- M
- race
- White
- new_clusters
- C5
- umap1_2d
- 6.37689389
- umap2_2d
- 5.273555421
- umap1_3d
- 3.103789509
- umap2_3d
- -0.43405893
- umap3_3d
- -2.171489559
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.260
- WNT_BETA_CATENIN_SIGNALING+0.260
- TNFA_SIGNALING_VIA_NFKB+0.210
- HEDGEHOG_SIGNALING+0.180
- PANCREAS_BETA_CELLS+0.180
- ALLOGRAFT_REJECTION+0.160
- INFLAMMATORY_RESPONSE+0.090
- KRAS_SIGNALING_UP+0.080
- SPERMATOGENESIS+0.080
- ESTROGEN_RESPONSE_EARLY+0.070
Top 10 suppressed
- E2F_TARGETS-0.540
- OXIDATIVE_PHOSPHORYLATION-0.490
- G2M_CHECKPOINT-0.470
- MYC_TARGETS_V1-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- DNA_REPAIR-0.410
- MYC_TARGETS_V2-0.390
- INTERFERON_ALPHA_RESPONSE-0.380
- UNFOLDED_PROTEIN_RESPONSE-0.380
- PROTEIN_SECRETION-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12696780 | — | — | 0.858 |
| 2 | BS_8PNA0V6R | high-grade glioma | — | 0.840 |
| 3 | MNG1092 | — | — | 0.836 |
| 4 | BS_W9AT0MR7 | Med | Medulloblastoma | 0.831 |
| 5 | MNG1149 | — | — | 0.830 |
| 6 | BS_A14Z8BBK | Med | Medulloblastoma | 0.829 |
| 7 | MNG1150 | — | — | 0.828 |
| 8 | MNG243 | — | — | 0.826 |
| 9 | MNG777 | — | — | 0.825 |
| 10 | dab9a230-f4f6-4692-863a-5fdcf516be24 | — | — | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.090 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |